RUBICON.NS
RUBICON.NS
INE506V01022
RUBICON RESEARCH LIMITED
Loading chart...

Company Profile

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.

Related stocks

GLAXO.NS
GLAXO.NS • India
GLAXOSMITHKLINE PHARMA LT
2,540.3 INR
4.45B USD 1Y -8%
MARKSANS.NS
MARKSANS.NS • India
MARKSANS PHARMA LIMITED
309.1 INR
1.45B USD 1Y +82.4%
PFIZER.NS
PFIZER.NS • India
PFIZER LTD
3,808.2 INR
1.8B USD 1Y -27.7%
SANOFICONR.NS
SANOFICONR.NS • India
SANOFI CONS HEALTHC IND L
3,581.7 INR
853.55M USD 1Y -24.8%
4536.T
4536.T • Japan
SANTEN PHARMACEUTICAL CO
1,684 JPY
3.42B USD 1Y +7.8%
KLBF.JK
KLBF.JK • Indonesia
Kalbe Farma Tbk
785 IDR
1.99B USD 1Y -27.6%
SANOFI.BO
SANOFI.BO • India
SANOFI INDIA LTD
2,945.55 INR
700.95M USD 1Y -37%
002019.SZ
002019.SZ • China
YIFAN PHARM
9.66 CNY
1.76B USD 1Y -30.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
-
Max Drawdown (3Y)
-
Sharpe Ratio (3Y)
-
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 89.2 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende